Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485563 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Endocyte.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00485563: Clinical Trial Phase 2 study, sponsored by Endocyte.
NCT00485563 is a Phase 2 study that was terminated before completion, run by Endocyte. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00485563, a Phase 2 study, was terminated before completion, sponsored by Endocyte.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 \[KLH-FITC\] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination with low-dose cytokines in patients with progressive metastatic renal cell carcinoma. All patients will undergo imaging with the investigational imaging agent 99mTc-EC20 (FolateScan) during the screening period to confirm eligibility for the treatment portion of the clinical trial.
Interventions
- DRUG Interleukin-2
- DRUG Interferon-alpha
- BIOLOGICAL EC90 (KLH-FITC)
- BIOLOGICAL GPI-0100
- DRUG EC17 (Folate-FITC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00485563
The ClinicalTrials.gov registry entry for NCT00485563 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Interleukin-2 is the first listed.
NCT00485563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00485563 about?
NCT00485563 is a clinical study titled "A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma". This is a Phase 2 clinical trial to collect data on tumor responses produced by folate-hapten conjugate therapy (vaccination with EC90 \[KLH-FITC\] and GPI-0100 adjuvant followed by treatment with EC17 (folate-FITC) in combination with low-dose cytokines in patients with progressive metastatic renal...
What is the current status of trial NCT00485563?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-06. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00485563?
The interventions under investigation include: Interleukin-2 (DRUG), Interferon-alpha (DRUG), EC90 (KLH-FITC) (BIOLOGICAL), GPI-0100 (BIOLOGICAL), EC17 (Folate-FITC) (DRUG).
Who is sponsoring clinical trial NCT00485563?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.